Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Jun;96(25):e7258.
doi: 10.1097/MD.0000000000007258.

Association between polymorphic CAG repeat lengths in the androgen receptor gene and susceptibility to prostate cancer: A systematic review and meta-analysis

Affiliations
Meta-Analysis

Association between polymorphic CAG repeat lengths in the androgen receptor gene and susceptibility to prostate cancer: A systematic review and meta-analysis

Zhiqiang Qin et al. Medicine (Baltimore). 2017 Jun.

Abstract

Background: Previous studies have been conducted to reveal the relationship between androgen receptor CAG polymorphism and risk of prostate cancer, yet the results were elusive and controversial. Thus, this meta-analysis was performed to clarify this association.

Methods: To obtain the relevant available studies, online databases PubMed, Embase, and Web of science were searched until September 1st, 2016. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of such association. Subgroup analyses were conducted based on ethnicity and source of controls. Moreover, Begg's funnel plots and Egger's linear regression test were conducted to test the publication bias.

Results: Overall, our results enrolled 51 studies indicated that significant increased risk of prostate cancer was associated with androgen receptor CAG polymorphism (OR = 0.77, 95% CI: 0.67-0.89). In addition, compared with CAG repeat <20, 22, carriers of ≧20, 22 repeats had decreased risk of prostate cancer (cut-off point = 20: OR = 0.27, 95% CI: 0.13-0.52; cut-off point = 22: OR = 0.82, 95% CI: 0.70-0.97). However, when cut-off point = 23, no significant result was detected in such association (pooled OR = 0.88, 95% CI: 0.63-1.24). When cut-off point is 22, the results were positive only in Asian population (OR = 0.53, 95% CI: 0.32-0.89) in the subgroup analysis by ethnicity. Besides, when the studies were stratified by source of controls, the results were not significant in both the subgroup of population-based controls and hospital-based controls.

Conclusions: This meta-analysis suggested the carriers of short polymorphic CAG repeats might increase susceptibility to prostate cancer, which held potential as a detecting marker of the risk of prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow diagram of literature search and selection process.
Figure 2
Figure 2
Forest plots of the association between androgen receptor CAG polymorphism and prostate cancer susceptibility.
Figure 3
Figure 3
Forest plots of the association between androgen receptor CAG polymorphism and prostate cancer susceptibility. (A) Cut-off point  =  22; (B) cut-off point  =  23; (C) cut-off point  =  20.
Figure 4
Figure 4
Forest plots of subgroup analysis of the association between androgen receptor CAG polymorphism and prostate cancer susceptibility in the cut-off point of polymorphic CAG repeat lengths  =  22. (A) Stratified by ethnicity; (B) stratified by source of controls.
Figure 5
Figure 5
Begg's funnel plot of publication bias test. (A) Total studies; (B) cut-off point  =  22; (C) cut-off point  =  23; (D) cut-off point  =  20.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30. - PubMed
    1. Recine F, Sternberg CN. Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer. Transl Androl Urol 2015;4:355–64. - PMC - PubMed
    1. Discacciati A, Wolk A. Lifestyle and dietary factors in prostate cancer prevention. Recent Results Cancer Res 2014;202:27–37. - PubMed
    1. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859–64. - PubMed
    1. Lai GY, Giovannucci EL, Pollak MN, et al. Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study. Cancer Causes Control 2014;25:625–32. - PMC - PubMed